Rapid Micro Biosystems, Inc. is a life sciences technology company that provides automation solutions for manufacturing and releasing healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. Its flagship Growth Direct system modernizes and automates outdated microbial quality control testing workflows in pharmaceutical manufacturing. The system supports four applications: Environmental Monitoring for the manufacturing environment, Water for purified water in drug production, In-Process Bioburden for raw materials and in-process products, and Sterility Release for final product testing before release. The RPID average annual return since 2021 is shown above.
The Average Annual Return on the RPID average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether RPID average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the RPID average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|